This is the main mechanism by which empagliflozin suppresses IgE and type 2 immunity cytokines in MGO-exposed mice challenged with OVA, thus emerging as a promising therapeutic strategy, being particularly advantageous in asthma phenotypes linked to metabolic dysregulation, such as obesity and type 2 diabetes mellitus. Here, IGHE is linked to obesity disorder.